Theratechnologies (THERF) Rating Lowered to Hold at ValuEngine

ValuEngine lowered shares of Theratechnologies (OTCMKTS:THERF) from a buy rating to a hold rating in a research report report published on Wednesday.

Separately, Royal Bank of Canada started coverage on shares of Theratechnologies in a research report on Tuesday, September 4th. They set a sector perform rating for the company.

OTCMKTS:THERF opened at $5.57 on Wednesday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 2.52 and a current ratio of 2.89. Theratechnologies has a one year low of $5.06 and a one year high of $11.25.

Theratechnologies (OTCMKTS:THERF) last posted its earnings results on Thursday, October 4th. The company reported $0.02 EPS for the quarter. The company had revenue of $13.53 million during the quarter. Theratechnologies had a negative net margin of 17.11% and a negative return on equity of 17.75%.

About Theratechnologies

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. The company's lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada.

Featured Article: Capital Gains

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply